Evgen Pharma said Tuesday that its lead product, SFX-01, will be tested against triple negative breast cancer (TNBC) in new preclinical research at the Manchester Cancer Research Centre, UK... Subscribe to Read More...
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |